EDT Stock Overview
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America.
Spectral Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.46|
|52 Week High||CA$0.62|
|52 Week Low||CA$0.15|
|1 Month Change||13.58%|
|3 Month Change||55.93%|
|1 Year Change||37.31%|
|3 Year Change||22.67%|
|5 Year Change||15.00%|
|Change since IPO||-98.74%|
Recent News & Updates
|EDT||CA Biotechs||CA Market|
Return vs Industry: EDT exceeded the Canadian Biotechs industry which returned 11.1% over the past year.
Return vs Market: EDT exceeded the Canadian Market which returned 0.7% over the past year.
|EDT Average Weekly Movement||16.4%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: EDT is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: EDT's weekly volatility has increased from 11% to 16% over the past year.
About the Company
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy.
Spectral Medical Fundamentals Summary
|EDT fundamental statistics|
Is EDT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EDT income statement (TTM)|
|Cost of Revenue||CA$956.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.038|
|Net Profit Margin||-676.47%|
How did EDT perform over the long term?See historical performance and comparison
Is EDT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EDT?
Other financial metrics that can be useful for relative valuation.
|What is EDT's n/a Ratio?|
Price to Book Ratio vs Peers
How does EDT's PB Ratio compare to its peers?
|EDT PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
COV Covalon Technologies
BCT BriaCell Therapeutics
ONC Oncolytics Biotech
APS Aptose Biosciences
EDT Spectral Medical
Price-To-Book vs Peers: EDT is good value based on its Price-To-Book Ratio (-175.6x) compared to the peer average (2.6x).
Price to Earnings Ratio vs Industry
How does EDT's PE Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Book vs Industry: EDT is good value based on its Price-To-Book Ratio (-175.6x) compared to the Canadian Biotechs industry average (2.7x)
Price to Book Ratio vs Fair Ratio
What is EDT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||-175.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate EDT's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of EDT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EDT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EDT's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at Spectral Medical's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Spectral Medical regulatory filings.
How is Spectral Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: EDT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EDT is expected to become profitable in the next 3 years.
Revenue vs Market: EDT's revenue (94.8% per year) is forecast to grow faster than the Canadian market (6.7% per year).
High Growth Revenue: EDT's revenue (94.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Spectral Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDT is currently unprofitable.
Growing Profit Margin: EDT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDT is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare EDT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: EDT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Spectral Medical's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EDT is debt free.
Reducing Debt: EDT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EDT has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.7% each year.
Discover healthy companies
What is Spectral Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EDT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Christopher Seto, also known as Chris, serves as Director for Spectral Medical Inc. since November 12, 2021. He has been Chief Executive Officer of Spectral Medical Inc. since April 1, 2021. Mr. Seto h...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD673.91K) is above average for companies of similar size in the Canadian market ($USD186.79K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
Experienced Management: EDT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: EDT's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EDT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Spectral Medical Inc.'s employee growth, exchange listings and data sources
- Name: Spectral Medical Inc.
- Ticker: EDT
- Exchange: TSX
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$123.351m
- Shares outstanding: 268.15m
- Website: https://www.spectraldx.com
Number of Employees
- Spectral Medical Inc.
- 135 The West Mall
- Unit 2
- M9C 1C2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/13 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.